Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2024-02-22 Intervacc Intervacc tidigarelägger årsstämma och rapport för första kvartalet 2024 Pressreleaser Ladda ner | Visa Stäng
2024-02-22 Intervacc Intervacc announces changes in dates for AGM and report for the first quarter 2024 Pressreleaser Ladda ner | Visa Stäng
2024-02-21 Penser Access by Carnegie Penser Access by Carnegie: Intervacc - Behöver visa tillväxt Pressreleaser Visa Stäng
2024-02-16 Intervacc Intervacc: Bokslutskommuniké januari - december 2023 Pressreleaser Ladda ner | Visa Stäng
2024-02-16 Intervacc Intervacc: Year-end report January - December 2023 Pressreleaser Ladda ner | Visa Stäng
2024-02-13 Intervacc Intervacc: Inbjudan till telefonkonferens och audiocast i samband med bokslutskommuniké Pressreleaser Ladda ner | Visa Stäng
2024-02-13 Intervacc Intervacc: Invitation to conference call and audiocast in connection with the year-end report Pressreleaser Ladda ner | Visa Stäng
2024-02-07 Intervacc Intervacc awarded prestigious Eurostars grant to advance their new prototype vaccine against Streptococcus suis infection in pigs Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 7 Feb 2024 | Intervacc

Intervacc awarded prestigious Eurostars grant to advance their new prototype vaccine against Streptococcus suis infection in pigs

Streptococcus suis causes meningitis, septicaemia and arthritis in young piglets, leading to significant costs to the pig industry throughout the world. Intervacc’s innovative vaccine technology utilises fusion proteins to generate broad-acting immune responses that provide protection to animals from complex bacterial diseases. A particular challenge for vaccines against S. suis is the onset of disease in very young pigs shortly after weaning, before most vaccines have an opportunity to take effect. However, in proof-of-concept studies, the consumption of colostrum from sows that were vaccinated with Intervacc’s prototype vaccine provided significant levels of protection to piglets against Streptococcus suis at both 4 and 7 weeks of age. The control of disease caused by S. suis currently requires the extensive use of antibiotics. S. suis is also an important cause of zoonotic disease in humans. Therefore, the development of a safe and effective vaccine that protects piglets is an urgent unmet need.

”We are delighted to have been awarded this Eurostars project grant, which will advance the development and optimisation of the scale-up production methods for our prototype vaccine in preparation for pivotal clinical trials,” said Dr. Andrew Waller, CSO of Intervacc. ”In addition, this project will optimise vaccine formulation and measure protection against a diverse type of S. suis, directing the design of the clinical trials.”

Rhona Macdonald, Managing Director of Moredun Scientific commented ”We look forward to continuing our collaboration with Intervacc, which brings our expertise in infectious disease models and porcine immunology to support the further development of their S. suis vaccine.”

The new €1.7 million Eurostars-3 programme award, provides a grant covering approximately 50% of the total project costs. The project will also be conducted in collaboration with Testa Center, the Swedish University of Agricultural Sciences and the Karolinska Institute.

”The award of this significant grant from Eurostars, in partnership with Vinnova, is further endorsement of our vaccine technology, and it’s utility to improve the health of animals and profitability of farms,” stated Jonas Sohlman, CEO of Intervacc. ”S. suis is a scourge of pig populations across the world and it is fantastic that we have the support of these influential organisations in taking this important step forward.”

For more information please contact:

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73

E-mail: jonas.sohlman@intervacc.se

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for immediate publication, through the agency of the contact person set out above on February 7, 2024.

About Eurostars

Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world.

Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 37 Eurostars Participating States and Partner Countries and by the European Union through Horizon Europe. From the start 2014 it has invested a total of about €1.75 billion in innovative research and development projects. Read more about Eurostars at https://www.eurostars-eureka.eu/

About Moredun Scientific

Moredun Scientific is a contract research organisation specialising in animal health and biosafety testing of biopharmaceuticals enabling companies to develop, register and commercialize their products. Their expert staff work with a global client base to ensure on time delivery of studies to the required quality standards. Read more at https://www.moredun.org.uk/commercial

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company’s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 – 684 211 10

2024-02-07 Intervacc Intervaccs tilldelas prestigefullt bidrag från Eurostars för vidareutveckling av sitt prototypvaccin till gris Pressreleaser Ladda ner | Visa Stäng
2023-12-21 Intervacc Intervacc announces changes in the Nomination Committee Pressreleaser Ladda ner | Visa Stäng
2023-12-21 Intervacc Förändringar av valberedningen i Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-12-11 Intervacc Intervacc: Europas ledande experter inom kvarka träffas vid riksanläggningen i Flyinge för att dela de senaste framstegen kring smittskydd och vaccination Pressreleaser Ladda ner | Visa Stäng
2023-12-11 Intervacc Intervacc: The National Equestrian Centre at Flyinge to host European expert meeting on the use of vaccination to prevent strangles in horses Pressreleaser Ladda ner | Visa Stäng
2023-11-23 Intervacc Report from Extraordinary General Meeting in Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-11-23 Intervacc Kommuniké från extra bolagsstämma i Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-11-22 Intervacc Intervacc beviljas patent i USA för vaccin mot infektioner orsakade av Streptococcus suis Pressreleaser Ladda ner | Visa Stäng
2023-11-22 Intervacc U.S. patent approval for Intervacc's vaccine against infections caused by Streptococcus suis Pressreleaser Ladda ner | Visa Stäng
2023-11-17 Penser Access Penser Access: IVACC Q3 2023 - Intervacc Pressreleaser Visa Stäng
2023-11-16 Intervacc Intervacc: Delårsrapport januari - september 2023 Rapporter Ladda ner | Visa Stäng
2023-11-16 Intervacc Intervacc: Interim report January - September 2023 Rapporter Ladda ner | Visa Stäng
2023-11-15 Intervacc Invitation to conference call with presentation of Intervacc's Interim report for the third quarter, 2023 Pressreleaser Ladda ner | Visa Stäng
2023-11-15 Intervacc Inbjudan till webcast i samband med Intervaccs delårsrapport för tredje kvartalet, 2023 Pressreleaser Ladda ner | Visa Stäng
2023-10-30 Intervacc Nomination Committee appointed in Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-10-30 Intervacc Valberedning utsedd i Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-10-19 Intervacc Intervacc: NOTICE OF EXTRAORDINARY GENERAL MEETING IN INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-10-19 Intervacc Intervacc: KALLELSE TILL EXTRA BOLAGSSTÄMMA I INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-09-01 Penser Access Penser Access: IVACC Q2’23 - Intervacc Pressreleaser Visa Stäng
2023-08-31 Intervacc Intervacc: Delårsrapport januari - juni 2023 Rapporter Ladda ner | Visa Stäng
2023-08-31 Intervacc Intervacc: Interim report January - June 2023 Rapporter Ladda ner | Visa Stäng
2023-08-21 Intervacc Andreas Andersson steps down as President and CEO. Jonas Sohlman has been appointed acting President and CEO for Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-08-21 Intervacc Andreas Andersson slutar som VD och koncernchef - Jonas Sohlman har utsetts som tillförordnad VD och koncernchef för Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-08-17 Intervacc Intervacc beviljas bidrag för att utveckla tillverkningsprocessen för ett prototypvaccin för grisar Pressreleaser Ladda ner | Visa Stäng
2023-08-17 Intervacc Intervacc awarded grant to optimise production processes for a fusion protein, which is one component of a prototype vaccine for pigs Pressreleaser Ladda ner | Visa Stäng
2023-07-11 Intervacc Intervacc to collaborate with Testa Center to optimise production processes for their prototype vaccine for pigs Pressreleaser Ladda ner | Visa Stäng
2023-07-11 Intervacc Intervaccs beviljas medel för uppstartsfasen i ett utvecklingsprojekt som avser att ta fram tillverkningsprocesser för ett prototypvaccin mot Streptococcus suis infektioner hos gris Pressreleaser Ladda ner | Visa Stäng
2023-07-10 Intervacc Intervacc ställer ut på Falsterbo Horse Show Pressreleaser Ladda ner | Visa Stäng
2023-06-08 Intervacc Intervacc offentliggör utfall i den fullt säkerställda företrädesemissionen Pressreleaser Ladda ner | Visa Stäng
2023-06-08 Intervacc Intervacc announces the outcome of the fully secured rights issue Pressreleaser Ladda ner | Visa Stäng
2023-06-07 Intervacc Report from Annual General Meeting in Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-06-07 Intervacc Kommuniké från årsstämman i Intervacc AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Intervacc Intervacc AB (publ) publishes prospectus in connection with a fully covered rights issue Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Intervacc Intervacc AB (publ) offentliggör prospekt i samband med fullt säkerställd företrädesemission Pressreleaser Ladda ner | Visa Stäng
2023-05-17 Intervacc Intervacc: The European Medicines Agency (EMA) approves extention of shelf life for Strangvac, a vaccine against equine strangles, to 33 months Pressreleaser Ladda ner | Visa Stäng
2023-05-17 Intervacc Intervacc: Europeiska läkemedelsmyndigheten (EMA) godkänner förlängning av hållbarheten för Strangvac, ett vaccin mot kvarka, till 33 månader Pressreleaser Ladda ner | Visa Stäng
2023-05-15 Penser Access Penser Access: Villkoren för företrädesemissionen kommunicerade - Intervacc Pressreleaser Visa Stäng
2023-05-11 Intervacc Styrelsen i Intervacc har beslutat om en fullt säkerställd företrädesemission om cirka 104 miljoner kronor Pressreleaser Ladda ner | Visa Stäng
2023-05-11 Intervacc The Board of Directors in Intervacc has resolved on a fully covered rights issue of approximately SEK 104 million Pressreleaser Ladda ner | Visa Stäng
2023-05-08 Intervacc Intervacc: Veterinary Medicines Directorate (VMD) förlänger hållbarheten för Strangvac, ett vaccin mot kvarka, till 33 månader i Storbritannien Pressreleaser Ladda ner | Visa Stäng
2023-05-08 Intervacc Intervacc: Veterinary Medicines Directorate (VMD) extends the shelf life for Strangvac, a vaccine against equine strangles, to 33 months Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Intervacc: CORRECTION: NOTICE OF ANNUAL GENERAL MEETING IN INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Intervacc: RÄTTELSE: KALLELSE TILL ÅRSSTÄMMA I INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Intervacc: NOTICE OF ANNUAL GENERAL MEETING IN INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Intervacc: KALLELSE TILL ÅRSSTÄMMA I INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Report from Extraordinary General Meeting in Intervacc Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Intervacc Kommuniké från extra bolagsstämma i Intervacc AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-04 Penser Access Penser Access: Försäljningsstarten tar längre tid än väntat - Intervacc Pressreleaser Visa Stäng
2023-05-03 Intervacc Intervacc: Delårsrapport januari - mars 2023 Rapporter Ladda ner | Visa Stäng
2023-05-03 Intervacc Intervacc: Interim report January - March 2023 Rapporter Ladda ner | Visa Stäng
2023-04-19 Intervacc Intervacc: NOTICE OF EXTRAORDINARY GENERAL MEETING IN INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-04-19 Intervacc Intervacc: KALLELSE TILL EXTRA BOLAGSSTÄMMA I INTERVACC AB (PUBL) Pressreleaser Ladda ner | Visa Stäng
2023-04-19 Intervacc Styrelsen i Intervacc avser att besluta om en fullt säkerställd företrädesemission om cirka 100 miljoner kronor Pressreleaser Ladda ner | Visa Stäng
2023-04-19 Intervacc The Board of Directors in Intervacc intends to resolve on a fully covered rights issue of approximately SEK 100 million Pressreleaser Ladda ner | Visa Stäng
2023-04-06 Intervacc Intervacc publicerar årsredovisning för 2022 Pressreleaser Ladda ner | Visa Stäng
2023-04-06 Intervacc Intervacc publishes the 2022 Annual Report Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

15 May 2024 | Årsstämma 2023
15 May 2024 | Kvartalsrapport 2024-Q1
13 Jun 2024 | Årligutdelning
30 Aug 2024 | Kvartalsrapport 2024-Q2
14 Nov 2024 | Kvartalsrapport 2024-Q3
13 Feb 2025 | Bokslutskommuniké 2024